SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF ABEMACICLIB IN THE TREATMENT OF HR+/HER2− ADVANCED OR METASTATIC BREAST CANCER . YHCĐ. 2026;67(10). doi:10.52163/yhc.v67i10.6967